Upadacitinib for recalcitrant extragenital morphea and lichen sclerosus overlap: A case report Authors: Taha Rasul, Christian E Hemmerich, Benjamin Cooper, Lily Tehrani, Karthik Krishnamurthy Published: 2026 Introduction Morphea and lichen sclerosus are inflammatory sclerosing disorders classified as distinct entities, yet they share overlapping clinical and histopathologic features.1 This overlap phenotype is uncommon but recognized and may reflect a shared fibrosing inflammatory pathway in a subset of patients. Extragenital lichen sclerosus is less common, but when associated with morphea-like induration and sclerosis, disease involvement can be extensive and therapeutically challenging.2 Management of recalcitrant morphea and lichen sclerosus overlap remains difficult, particularly when conventional therapies are ineffective or poorly tolerated. Standard treatments, including topical corticosteroids, phototherapy, methotrexate, and systemic immunomodulators, may provide incomplete control in patients with widespread disease.3 Janus kinase (JAK) inhibition has emerged as a potential therapeutic strategy in inflammatory and fibrosing dermatoses, but experience with upadacitinib in morphea and lichen sclerosus overlap remains limited. We report a case of biopsy-confirmed, recalcitrant extragenital morphea and lichen sclerosus overlap that demonstrated marked clinical improvement following initiation of upadacitinib after failure or intolerance of multiple conventional systemic therapies. Case report A 67-year-old female presented with progressive inflammatory and sclerosing dermatosis involving the trunk, inframammary folds, flanks, and proximal thighs without genital involvement. Examination demonstrated bound-down hyperpigmented plaques and white atrophic papules with telangiectasia, with moderate-to-severe disease involving up to 28% of body surface area (Fig 1). Symptoms included pain, pruritus, blistering, and reduced mobility. Punch biopsies reviewed by a dermatopathologist demonstrated morphea/lichen sclerosus overlap (Fig 2). Formal clinicopathologic correlation was performed, and direct immunofluorescence and PAS were negative. Clinical timeline is summarized below (Fig 3). Widespread indurated, erythematous, and hyperpigmented plaques involving the trunk and proximal thighs. A, Inframammary and upper abdominal involvement with erythematous, sclerotic plaques. B, Lateral trunk demonstrating erythematous plaques. C, Anterior and medial thigh showing hyperpigmented, atrophic plaques with textural skin changes. Hematoxylin and eosin (H&E) stained section (100×) of a 0.3 cm punch biopsy from the right lateral abdomen demonstrating epidermal atrophy with compact orthokeratosis, follicular plugging, and basal vacuolar/interface change overlying papillary dermal hyalinization, with underlying thickened sclerotic collagen bundles and adnexal entrapment in the deeper dermis, consistent with morphea–lichen sclerosus overlap. Treatment timeline and clinical course: Initial treatment with cyclosporine (CsO) showed no clinical response. Methotrexate (MTX) with prednisone led to partial improvement; however, dose escalation was limited by intolerance, including fatigue and disease flare. Transition to mycophenolate mofetil (MMF) and narrowband UVB (nbUVB) phototherapy led to transient improvement but was ultimately discontinued due to adverse effects, including nausea, weakness, and dizziness. Upadacitinib initiation at month 11 resulted in sustained clinical improvement. Colored markers reflect treatment phases and disease activity over time (red: progression or intolerance; blue: treatment period; green: sustained improvement). QD, Once daily. An initial 1-month trial of cyclosporine 150 mg daily was ineffective, with continued progression of increasing erythema, worsening induration, and painful plaque expansion. She was then transitioned to methotrexate 15 mg weekly with folic acid, monthly pulse prednisone, topical clobetasol and tacrolimus, and metformin in month 2. Early improvement was observed, with softening of plaques and decreased bulla tension, although pruritus remained significant and a new plaque developed on the right popliteal fossa. During follow-up through months 3-4, she continued to show incomplete improvement, including reduced pruritus, improved plaque induration, and return of sweating in previously affected areas, prompting escalation of methotrexate to 17.5 mg weekly in month 4. However, methotrexate was ultimately limited by severe post-dose fatigue, recurrent blistering, and ongoing need for intermittent prednisone pulses by months 4-5. Because of methotrexate intolerance, she was transitioned in month 5 to mycophenolate mofetil (MMF) and narrowband UVB phototherapy. By month 6, she improved on MMF 1000 mg twice daily with prednisone tapering, topical clobetasol, and calcium/vitamin D supplementation. Improvement persisted into months 7 to 9, although she developed persistent nausea, and her modified Rodnan skin score remained 12. By months 9 to 10, MMF was self-discontinued due to muscle weakness and dizziness. Although symptoms improved after discontinuation, disease activity persisted. Given failure or intolerance to cyclosporine, methotrexate, MMF, systemic corticosteroids, topical corticosteroids, topical tacrolimus, and narrowband UVB phototherapy, upadacitinib was initiated in month 11 after baseline laboratory screening. She had completed her prednisone taper 3 weeks earlier and had undergone 3 sessions of narrowband UVB. Upadacitinib 15 mg daily was initiated with aspirin 81 mg daily after discussion of the potential thrombotic risks associated with JAK inhibitor therapy and recent data suggesting increased thrombotic signaling with JAK inhibitor therapy.4 Narrowband UVB phototherapy, clobetasol, calcium, vitamin D supplementation, and antihistamines were continued. Within the first month, the patient reported marked improvement with reduced pruritus and lesion burden. At 2 months, further improvement in induration was observed with continued symptomatic relief (Fig 4). The modified Rodnan skin score decreased from a peak of 16 to 11; however, formal mean localized scleroderma skin severity index (mLoSSI) and localized scleroderma skin damage index (LoSDI) assessments were not performed. She remains on therapy with continued clinical improvement at 4 months of follow-up. Aside from mild acne managed with topical retinoids, upadacitinib was well tolerated without significant laboratory abnormalities or serious adverse events during follow-up. Clinical response 2 months following initiation of upadacitinib therapy with reduction in erythema, induration, and plaque burden involving the trunk and proximal thighs. A, Inframammary region demonstrating decreased erythema. B and C, Thighs showing reduced erythema, improved skin texture, and softening of plaques. D, Abdominal folds demonstrating improved induration and skin texture. E, Lateral trunk with reduced plaque prominence and softening. Discussion Management of morphea and lichen sclerosus overlap remains challenging when the disease is extensive and conventional therapies are ineffective or poorly tolerated. Cao et al reported that lichen sclerosus and morphea coexist in 5.7% of cases, underscoring that this overlap phenotype is uncommon. In the same report, a 53-year-old woman with morphea-lichen sclerosis overlap of the hand that was refractory to topical clobetasol improved with upadacitinib 15 mg daily, with lesion softening and pain improvement by 3 weeks, significant improvement by 3 months, and near resolution by 6 months.5 Additional reports further support a potential role for upadacitinib in morphea-spectrum disease. Maione et al described a 77-year-old woman with refractory morphea of the legs who had previously received UVA1 phototherapy, systemic corticosteroids, methotrexate, and MMF, but then substantially improved after upadacitinib 15 mg daily, with marked softening and resolution of ulcerative lesions at 3 months.6 Broader evidence remains limited to early reports and case series. Zheng et al identified 45 patients with localized scleroderma treated with JAK inhibitors, of whom 41 (91.1%) demonstrated skin improvement, while Su et al reported clinical improvement in all 6 juvenile patients who completed follow-up on upadacitinib 15 mg daily, with mLoSSI decreasing from 8.2 to 1.8 and mean localized scleroderma skin damage index (LoSDI) from 12.5 to 3.2.7,8 Taken together, these reports suggest upadacitinib may have therapeutic potential in refractory morphea-spectrum disease, including morphea-lichen sclerosis overlap. Upadacitinib may provide therapeutic benefits in morphea and lichen sclerosus because both diseases are characterized by interferon-driven inflammation and enhanced JAK-STAT signaling. Morphea shows upregulation of IFN-γ-associated chemokines that promote immune cell recruitment and fibroblast activation, while lichen sclerosus likewise demonstrates Th1-skewed inflammation with increased IFN-γ/JAK-STAT activity.9,10 By selectively inhibiting JAK1, upadacitinib may attenuate both inflammatory signaling and downstream profibrotic pathways involved in fibroblast activation and collagen deposition.7,8 Conclusion This case highlights the utility of upadacitinib in recalcitrant extragenital morphea and lichen sclerosus overlap, particularly in a patient with extensive disease, and failure or intolerance of multiple conventional systemic therapies. Considering the limited treatment options for refractory overlap disease, this report supports further evaluation of selective JAK1 inhibition in larger cohorts to better define its durability, safety, and potential role in the treatment of patients. Conflicts of interest None disclosed. Footnotes Funding sources: None. Disclaimer: This research was supported (in whole or in part) by HCA Healthcare and/or an HCA Healthcare-affiliated entity. The views expressed in these publications represent those of the authors and do not necessarily represent the official views of HCA Healthcare or any of its affiliated entities. Patient consent: The authors obtained written consent from the patient for their photographs and medical information to be published in print and online, with the understanding that this information may be publicly available. Patient consent forms were not provided to the journal but are retained by the authors. All identifying information has been removed to protect patient privacy. IRB approval status: Not applicable. References